Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab plus paclitaxel and carboplatin in triple-negative breast cancer
NCT07283692Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in triple-negative breast cancer (TNBC), sponsored by Renji Hospital. Started Mar 2026; status: recruiting.
02
Drugs
serplulimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07283692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283692.